The glomerulopathy of sickle cell disease

Kenneth I. Ataga, University of North Carolina
Vimal K. Derebail, University of North Carolina
David Archer, Emory University

Journal Title: American Journal of Hematology
Volume: Volume 89, Number 9
Publisher: Wiley Periodicals Inc. | 2014-06-18, Pages 907-914
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1002/ajh.23762
Permanent URL: https://pid.emory.edu/ark:/25593/s2v0h

Final published version: http://dx.doi.org/10.1002/ajh.23762

Copyright information:
© 2014 The Authors American Journal of Hematology Published by Wiley Periodicals, Inc.
This is an Open Access work distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/).

Accessed November 22, 2018 11:25 PM EST
Sickle cell disease (SCD) produces many structural and functional abnormalities in the kidney, including glomerular abnormalities. Albuminuria is the most common manifestation of glomerular damage, with a prevalence between 26 and 68% in adult patients. The pathophysiology of albuminuria in SCD is likely multifactorial, with contributions from hyperfiltration, glomerular hypertension, ischemia-reperfusion injury, oxidative stress, decreased nitric oxide (NO) bioavailability, and endothelial dysfunction. Although its natural history in SCD remains inadequately defined, albuminuria is associated with increased echocardiography-derived tricuspid regurgitant jet velocity, systemic blood pressure, and hypertension, as well as history of stroke, suggesting a shared vasculopathic pathophysiology. While most patients with albuminuria are treated with angiotensin converting enzyme inhibitors/angiotensin receptor blockers, there are no published long-term data on the efficacy of these agents. With the improved patient survival following kidney transplantation, SCD patients with end-stage renal disease should be considered for this treatment modality. Given the high prevalence of albuminuria and its association with multiple SCD-related clinical complications, additional studies are needed to answer several clinically important questions in a bid to adequately elucidate its pathophysiology, natural history, and treatment.

Introduction

Sickle cell disease (SCD), one of the most common monogenic disorders worldwide, results in many structural and functional abnormalities in the kidney, including abnormalities of tubular function, hematuria, and glomerular abnormalities [1]. The kidney is particularly sensitive to the effects of hypoxia because of its high rate of oxygen consumption [2]. Due to the presence of acidosis, hypertonicity and hypoxia in the environment of the renal medulla, this portion of the kidney is very susceptible to changes in oxygen delivery. As blood traverses the slow-moving circuit of the medullary vasa recta, the hyperosmolar milieu may enhance dehydration of red blood cells (RBCs), allowing polymerization of sickle hemoglobin (HbS) and resulting in vaso-occlusion and medullary microinfarction [3,4]. Indeed, microangiopathic studies show the loss of vasa recta in older patients with SCD, with those that remain being abnormally dilated or blunted [5]. This review will focus on albuminuria, the most common clinical manifestation of glomerular damage in SCD.

Renal Pathology in SCD

In young SCD patients with normal renal function, the kidneys are enlarged, with a smooth capsular surface [6]. With advancing age and the development of chronic renal failure, the kidneys become scarred and shrunken, with the capsular surface ranging from coarsely granular to grossly distorted and scarred [6]. Unlike in normal individuals, glomerular size increases with age in SCD [6]. These enlarged, markedly hypercellular glomeruli exhibit lobulation of the glomerular tuft on histological examination. In the early stages of sickle cell nephropathy, renal biopsy shows glomerular hypertrophy, hemosiderin deposits, and focal areas of hemorrhage or necrosis [7,8]. In later stages, interstitial inflammation, edema, fibrosis, tubular atrophy, and papillary infarcts are commonly observed, with these changes mostly due to vascular dropout [7,8]. A multicenter retrospective survey of 18 SCD patients (HbSS—16; HbSC—1; 1 HbSβ-thalassemia—1) who underwent renal biopsies for isolated proteinuria or in association with acute or progressive impairment of renal function showed focal segmental glomerulosclerosis (FSGS) in seven cases, membranoproliferative glomerulonephritis (MPGN) in five cases, thrombotic microangiopathic glomerulopathy in three cases, and glomerular hypertrophy with or without mesangial hypercellularity (early sickle cell disease glomerulopathy) in three cases, suggesting a wide spectrum of glomerular lesions in SCD [9]. Regardless of the observed morphologic lesion, glomeruli were enlarged and the capillaries were distended by sickled RBCs. Of the seven FSGS cases, exclusive not otherwise specified (NOS) lesions were seen in three cases, NOS lesions associated with tip lesions in two cases and two cases showed concomitant tip lesions and perihilar lesions [9]. A collapsing pattern of FSGS has also been reported [10].

Conflict of interest: KIA is a consultant for Pfizer and Celgene, and has served on scientific advisory boards for Adventrx, HemaQuest, Sangart, Selyexis, and Biogen Idec.

Correspondence to: Kenneth I. Ataga, MBBS; Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Physicians’ Office Bldg., 3rd Floor, CB# 7305, 170 Manning Drive, Chapel Hill, NC 27599-7305. E-mail: kataga@med.unc.edu

Contract grant sponsor: NIH; Contract grant number: RO1 HL111659 (to KIA, VKD, DRA).

Received for publication: 14 May 2014; Accepted: 14 May 2014

Glomerular changes that are indistinguishable from those of proliferative glomerulonephritis may be seen in SCD patients with no apparent renal disease [6]. Reduplication of the basement membrane and mesangial proliferation are also seen in SCD, especially as patients’ age. Immunofluorescence microscopy in patients with FSGS type lesions demonstrates irregular staining for IgM and C3 in areas of sclerosis [7,8,10], and MPGN lesions demonstrate capillary wall staining for IgG, IgM, IgA, C3, and C1q [10]. Electron microscopy of glomeruli in SCD patients with proteinuria or the nephrotic syndrome show effacement of the podocyte foot processes, with occasional wrinkling of the capillary wall, usually associated with partial or complete mesangial interposition [8].

Transgenic mouse models of SCD show findings similar to those observed in human sickle cell glomerulopathy. The transgenic SAD mouse bears the human α-globin gene and the HbS mutation, βS, as well as β2Hb-Antilles and β2Hb-Punjab, which greatly enhance the tendency of its hemoglobin to polymerize. The renal pathology of the SAD mouse shows glomerular hypertrophy and mesangial sclerosis, which increase in frequency and severity as the mice age [11]. Glomerular damage is associated with increased levels of blood urea nitrogen and nonselective proteinuria. Other renal changes in these mice include hemosiderosis, cortical infarcts, and papillary necrosis. In sickle mice that exclusively express the human α- and βS-globin (Berkeley mice), kidney weights are increased 2-fold, and histologic analysis shows fibrosis, atrophy, infarcts, and cysts, with increased iron deposits in the tubular epithelium [12]. Hämizygous sickle mice expressing human α- and β2-globin (Los Angeles mice), kidney hypertrophy, glomerulosclerosis, atrophy, and hyaline plaques are seen [13]. The renal tubular epithelium shows mild to severe renal lesions including glomerulonephritis, dilated tubules, atypical tubules, tubular degeneration, mild necrosis, and interstitial fibrosis in about 50% of mice [13]. The renal tubular epithelium shows increased expression of inducible nitric oxide (NO) synthase and 3-nitrotyrosine, as well as increased staining for vascular cell adhesion molecule-1 (VCAM-1) in the interstitial capillary cells and tubular epithelial cells compared with normal control mice.

### Pathophysiology

The relative hypoxia, acidosis, and hyperosmolarity of the inner medulla favor polymerization of deoxygenated Hbs and subsequent sickling of RBCs. These repeated cycles of sickling are thought to lead to ischemic injury and microinfarction, which ultimately result in reduced medullary blood flow. Worsening hypoxia results in localized prostaglandin release and marked vasoconstriction, which increases renal blood flow and hence glomerular filtration rate (GFR). Indirect measurements of renal prostaglandin activity have been performed by observing the effects of the prostaglandin synthesis inhibitor, indomethacin. Following administration of indomethacin, GFR and effective renal plasma flow (ERPF) fell significantly in HbSS patients but remained unchanged in control subjects [14], suggesting that prostaglandins are important in maintaining the supranormal levels of GFR and ERPF observed in SCD. The association of increased GFR in HbSS patients with albuminuria raises the possibility that hyperfiltration may contribute to renal damage [15–18] (Table I). If, indeed, hyperfiltration is a necessary precursor of glomerulopathy in SCD, then endogenous perturbation of the prostaglandin systems could explain the early development of FSGS in this setting. Hyperfiltration also may lead to endothelial hyperplasia and ultimately glomerular fibrosis [31,32].

The pathophysiology of sickle cell glomerulopathy has been reported to resemble that which develops in rodents following subtotal nephrectomy [7,8,19]. In these animals, glomerular hypertension in the remaining hypertrophied glomeruli may result in glomerular sclerosis [20]. The observation that glomerular hypertension is attenuated by angiotensin converting enzyme inhibitors in rodents, combined with the quick and reversible decrease in protein excretion in HbSS patients receiving these agents gives further credence to the possibility that this mechanism contributes to SCD-related glomerulopathy [7,20].

Transgenic mice homozygous for the murine β-globin deletion that carry two transgenes, αHbS-Antilles and αHbS-Antilles-HbA, exhibit oxidative stress in the kidney as indicated by increased amounts of lipid peroxidation [21]. Exacerbation of oxidative stress increased sickling of RBCs, extending from the medulla into the cortical capillaries and glomeruli. In these sickle mice, renal ischemia following total renal artery occlusion for 15 min resulted in a significant increase in creatinine and blood urea nitrogen levels that was associated with diffuse acute tubular necrosis extending across the entire width of the cortex, with large segments of cortical necrosis [22]. Six hours after bilateral renal ischemia for 22.5 min, the sickle mice showed greater renal histological injury than wild-type mice with extensive tubular necrosis extending from the corticomedullary junction through the full thickness of the cortex accompanied by marked congestion in peritubular capillaries and an acute glomerulopathy consisting of endothelialitis and mesangiolysis [22]. These latter changes along with accompanying reparative responses, especially if incurred through repetitive cycles of renal ischemia, may contribute to a chronic glomerulopathy in SCD (Fig. 1).

Figure 1. Proposed mechanisms of glomerulopathy in sickle cell disease. Multiple mechanisms may contribute to the pathogenesis of glomerular damage in sickle cell disease. These may occur due to changes in the renal vasculature, peritubular capillaries and the glomerulus. PG: prostaglandin; NO: nitric oxide; ANP: atrial natriuretic peptide; ROS: reactive oxygen species; sFLT-1: soluble fms-like tyrosine kinase-1; VEGF: vascular endothelial growth factor; ANG-II: angiotensin II; TGF-β: transforming growth factor-β; TNFα: tumor necrosis factor-α; ET-1: endothelin-1.
the renal response to acute ischemic injury [23]. As the phosphorylated form of these signaling proteins usually determines the active moiety, the recruitment of signaling processes following ischemia is markedly impaired in the kidney of sickle mice. The impaired phosphorylation of mitogen-activated protein kinase (MAPK) and Akt proteins in the kidney following ischemia may partly be due to decreased renal ATP content and correlates with increased expression of TNF-α, an inflammatory cytokine which may contribute to the increased sensitivity of the kidney to ischemia in sickle mice [23].

More recent data appear to confirm the role of oxidative stress in sickle cell glomerulopathy. Reactive oxygen species (ROS) increase the conversion of oxidized angiotensinogen to angiotensin II (ATII), and increase secondary angiotensin receptor 1 (AT1R)-mediated generation of transforming growth factor-beta 1 (TGF-β) in the kidney in SCD, which then phosphorylates Smad 2/3 [24]. In young sickle mice, blockade of the AT1R with losartan, or its ligand ATII by an angiotensin converting enzyme inhibitor, captopril, prevented albuminuria and FSGS development but worsened hyposthenuria, suggesting that excessive AT1R signaling causes sickle cell glomerulopathy, while AT1R promotes urine concentrating ability. Furthermore, AT1R signaling is known to activate NADPH oxidase to generate ROS and mice treated with captopril and losartan had reduced ROS in RBC, platelets as well as the kidneys, and consequently reduced renin-angiotensin system activation.

The level of soluble fms-like tyrosine kinase-1 (sFLT-1) is elevated in patients with SCD patients compared to healthy, race-matched control subjects [33,34]. sFLT-1 is a member of the vascular endothelial growth factor receptor (VEGFR) family [35] and is a splice variant of VEGFR1. VEGF, a well-known promoter of angiogenesis and an endogenous regulator of endothelial integrity promotes endothelial cell survival and angiogenesis through activation of the protein kinase, Akt, which in turn activates endothelial NO synthase and increases NO generation [36]. By antagonizing VEGF action and inhibiting Akt phosphorylation, sFLT-1 decreases NO bioavailability, thus leading to endothelial dysfunction. sFLT-1 has been linked with pre eclampsia, a condition characterized by hypertension, proteinuria, and endothelial dysfunction [37]. We have shown that SCD patients with macroalbuminuria have significantly higher levels of sFLT-1 and soluble VCAM-1 compared to patients with lower levels of albuminuria [25]. The association of albuminuria with soluble VCAM-1, combined with the association of sFLT-1 with soluble VCAM-1, suggests that sFLT-1 may contribute to the pathogenesis of albuminuria in SCD by promoting endothelial dysfunction [25].

Multiple observational studies show an association of albuminuria with markers of hemolysis in patients with SCD [26–29], although other studies have not shown such associations [18,25,38,39]. Chronic depletions of NO due, at least in part, to scavenging by cell-free hemoglobin from ongoing intravascular hemolysis, may contribute to the glomerulopathy in SCD. In addition, the activation of hypoxia-inducible factor 1α and the consequent increase in local endothelin-1 release, in the presence of reduced NO, leads to an increase in ROS and vasoconstriction, contributing to a cycle of chronic medullary hypoxia [40,41]. We have shown an association of sFLT-1 with markers of hemolysis [34] suggesting that sFLT-1 may be downstream of hemolysis, and increased sFLT-1 levels may further decrease the bioavailability of NO in SCD. NO deficiency has been demonstrated in individuals with chronic kidney disease, and this may lead to progression of chronic kidney disease [42]. Indeed, animal studies show that chronic inhibition of NO synthase causes systemic and glomerular hypertension, glomerular ischemia, glomerulosclerosis, tubulointerstitial injury, and proteinuria [43]. With the increasing evidence that hemolysis may play a role in the vasculopathy of SCD [44], hemolysis and NO deficiency may also contribute to the development of glomerulopathy in SCD.

Chronic treatment of transgenic sickle mice with morphine for 3–6 weeks has been reported to produce defects in renal pathology, including increased glomerular volume, mesangial expansion, mesangial cell proliferation, parietal cell metaplasia, podocyte effacement, and microvillus transformation [30]. Chronic treatment with morphine also increased the expression and activity of heme oxygenase-1, and increased albuminuria [30]. The renal effects of morphine are ameliorated by naloxone, a nonselective opioid antagonist, suggesting that opioid receptor antagonists may be effective in decreasing morphine-induced renal disease.

## Clinical Implications

The normal rate of urinary albumin excretion is less than 20 mg/day (15 mcg/min), and is usually between 4 and 7 mg/day in healthy young adults. Persistent excretion of albumin between 30 and 300 mg/day (20–200 mcg/min) is called microalbuminuria, while albumin excretion above 300 mg/day (200 mcg/min) is considered overt proteinuria or macroalbuminuria. The standard urine dipstick primarily detects albumin, and is only semiquantitative. While very specific, the standard dipstick test is not sensitive to low levels of albuminuria and will not usually identify those with microalbuminuria. The gold standard for quantitative assessment of albuminuria is a 24-hr urine collection. Although proteinuria can be assessed by measuring the ratio of protein-to-creatinine (or albumin-to-creatinine ratio) from a spot first- or second-morning sample, this method has not been validated in SCD. In a study of 25 patients with albuminuria, albumin-to-creatinine ratio was reported to correlate with 12-hr urinary albumin excretion [45]. However, no correlations were observed in the percent change (from the first measurements) following treatment with angiotensin converting enzyme inhibitors at the times of second and third measurements of 12-hr urinary albumin excretion and albumin-to-creatinine ratio [45]. In another small study, the presence of microalbuminuria diagnosed by spot urine albumin-to-creatinine ratio in 19 patients was confirmed by 24-hr urine collection in only 57% of cases [46].

The prevalence of albuminuria in SCD increases with age, varying between 4.5 and 26% in patients up to 21 years [46–52], and between 26 and 68% in older patients [7,15,25,38,53,54]. Although a prospective, 25-year case-control study reported that 9 of 21 HBSS patients with nephrotic syndrome developed chronic renal failure [55], the natural history of albuminuria in SCD remains inadequately defined. A small study of 38 patients, 30 of whom had microalbuminuria and eight with macroalbuminuria, showed progression of albuminuria in two patients with microalbuminuria and two patients with macroalbuminuria after approximately 20 months of follow-up [56]. In a retrospective study of 14 patients, with estimated GFR at the time of kidney biopsy ranging from 24 to 158 mL/min per m² and urine albumin excretion at the time of kidney biopsy ranging from 0.4 to 33 g/day, seven patients had chronic kidney disease and three patients required chronic intermittent hemodialysis due to ESRD after an average follow-up of 28 months (range, 4–79 months) [9]. Evaluation for proteinuria was only available in 12 patients, and a decrease in urinary protein was noted in 67% of patients treated with ATII receptor blockers or angiotensin converting enzyme inhibitors. In a more recent retrospective, single center study of 98 SCD patients, grade A3 albuminuria (adjusted odds ratio [OR], 5.0; 95% confidence interval [CI], 1.1–24.3; \( P = 0.0480 \)) and each 1 mm Hg increase in systolic blood pressure (adjusted OR, 1.04; 95% CI, 1.0–1.07; \( P = 0.039 \)) were associated with the development and progression of chronic kidney disease on multivariate analysis after 5 years of follow-up [57]. In this study, grade A3 proteinuria was defined as a urine protein-to-creatinine ratio greater than 500 mg/g, based on the 2012 KDIGO clinical practice guidelines [58].
<table>
<thead>
<tr>
<th>Reference</th>
<th>Number of patients</th>
<th>Mean or median age/range</th>
<th>Type of study</th>
<th>Measurement</th>
<th>Prevalence</th>
<th>Comments</th>
</tr>
</thead>
</table>
| Alvarez et al. [46] | 120 | 4–20 years | Retrospective | Microalbuminuria | 15.8%     | • Increased age associated with microalbuminuria.  
  • Early transfusion protective of microalbuminuria.  
  • Positive correlation with acute chest syndrome.  
  • More common in patients older than 10 years.  
  • Increasing age only variable associated with microalbuminuria.  
  • Increased age and lower hemoglobin correlated with microalbuminuria.  
  • Four of nine patients receiving hydroxyurea demonstrated regression of microalbuminuria.  
  • Increased age and lower hemoglobin in patients with microalbuminuria.  
  • Treatment with hydroxyurea resulted in reduction in hyperfiltration, with associated decrease in LDH and increase in HbF levels.  |
| Dharnidharka et al. [47] | 102 | 2–18 years | Prospective | Microalbuminuria | 26.5%     | More common in patients older than 10 years.  
  • Increasing age only variable associated with microalbuminuria.  |
| McBurney et al. [49] | 142 | 21 months–20 years | Retrospective | Microalbuminuria | 19%       | Increased age and lower hemoglobin correlated with microalbuminuria.  
  • Four of nine patients receiving hydroxyurea demonstrated regression of microalbuminuria.  
  • Increased age and lower hemoglobin in patients with microalbuminuria.  
  • All subjects treated with hydroxyurea.  
  • After 3 years of therapy, microalbuminuria resolved in two patients, persisted in two patients, and two patients developed new microalbuminuria.  |
| McKie et al. [50] | 191 | 3–20 years | Prospective | Microalbuminuria | 19.4%     | Increased age and lower hemoglobin in patients with microalbuminuria.  |
| McPherson Yee et al. [51] | 410 | 2–21 years | Cross sectional | Microalbuminuria | 20.7%     | Increased age and lower hemoglobin in patients with microalbuminuria.  
  Four of nine patients receiving hydroxyurea demonstrated regression of microalbuminuria.  
  • Increased age and lower hemoglobin in patients with microalbuminuria.  
  • All subjects treated with hydroxyurea.  |
| Aygun et al. [17] | 23 | 2.5–14 years | Prospective | Microalbuminuria | 17.4%     | All subjects treated with hydroxyurea.  
  • After 3 years of therapy, microalbuminuria resolved in two patients, persisted in two patients, and two patients developed new microalbuminuria.  |
| Thompson et al. [15] | 65 | 18–23 years | Cross sectional | Albuminuria | 26.2%     | eGFR and SBP correlated positively with albumin excretion.  
  • Serum sodium and hematocrit correlated negatively with albumin excretion.  
  • DBP associated with albuminuria.  
  • Albuminuria more common with worsening CKD stage.  
  • Lower hemoglobin associated with albuminuria.  
  • Hydroxyurea use associated with a third lower likelihood of albuminuria.  
  • Weak correlation with age and albumin excretion.  
  • eGFR lowest in patients with macroalbuminuria.  
  • NT-proBNP, sFLT-1 higher in patients with macroalbuminuria.  
  • Higher TRV with macroalbuminuria.  
  • Association of urine albumin excretion with suspected pulmonary hypertension and history of stroke.  
  • Among HbSS and HbSβ0 patients, albuminuria associated with VCAM-1 and hypertension.  
  • Higher prevalence in HbSS (68%).  
  • Prevalence of albuminuria increased with age.  
  • Albuminuria associated with age, irreversibly sickled RBC, creatinine, packed cell volume and asymptomatic bacteriuria.  
  • Irreversibly sickled RBC only independent predictor of albuminuria.  |
| Bolarinwa et al. [61] | 68 | 15–60 years | Cross sectional | Albuminuria | 50.0%     | Albuminuria more common with worsening CKD stage.  
  • Lower hemoglobin associated with albuminuria.  
  • Hydroxyurea use associated with a third lower likelihood of albuminuria.  |
| Laurin et al. [54] | 149 | 18–71 years | Retrospective | Albuminuria | 45.0%     | Albuminuria more common with worsening CKD stage.  
  • Lower hemoglobin associated with albuminuria.  
  • Hydroxyurea use associated with a third lower likelihood of albuminuria.  |
| Ataga et al. [25] | 73 | 39 years | Cross sectional | Albuminuria | 53.4%     | Albuminuria more common with worsening CKD stage.  
  • Lower hemoglobin associated with albuminuria.  
  • Hydroxyurea use associated with a third lower likelihood of albuminuria.  |
| Guasch et al. [38] | 300 | 19–76 years | Cross sectional | Albuminuria | 58%       | Albuminuria more common with worsening CKD stage.  
  • Lower hemoglobin associated with albuminuria.  
  • Hydroxyurea use associated with a third lower likelihood of albuminuria.  |
| Iwalokun et al. [52] | 103 | 10.4 years | Cross sectional | Albuminuria | 22.3%     | Albuminuria more common with worsening CKD stage.  
  • Lower hemoglobin associated with albuminuria.  
  • Hydroxyurea use associated with a third lower likelihood of albuminuria.  |
| Asnani et al. [39] | 121 | 24.1–32.5 years | Cross sectional | Albuminuria | 33.6%     | Albuminuria more common with worsening CKD stage.  
  • Lower hemoglobin associated with albuminuria.  
  • Hydroxyurea use associated with a third lower likelihood of albuminuria.  |
| Wigfall et al. [48] | 442 | 2–21 years | Prospective | Proteinuria (urinalysis) | 4.5% | Increased prevalence with age.  
  • Associated with stroke, acute chest syndrome, hospitalizations, and cholelithiasis.  |
Glomerulopathy and sickle cell disease

Continued

Table II. Continued

<table>
<thead>
<tr>
<th>Reference</th>
<th>Type of study</th>
<th>Number of patients</th>
<th>Mean or median age range</th>
<th>Prevalence</th>
<th>Comments</th>
</tr>
</thead>
</table>
| Folk et al. [7] | Prospective | 361 | 23 ± 7 years | 26% | Proximal tubular proteinuria associated with TRV ≥ 2.5 m/s in patients with HbSS.
| Almerrah et al. [58] | Cross-sectional | 67 | 23 ± 17 years | 40.3% | Proteinuria inversely correlated with eGFR in patients with HbSS.
| De Castro et al. [59] | Prospective | 542 | 18–84 years | 26% | Proteinuria inversely correlated with eGFR in patients with HbSS.
| Forrest et al. [60] | Prospective | 85 | 6–21 years | N/A | Proteinuria inversely correlated with eGFR in patients with HbSS.

Albinininuria is more prevalent in HbSS patients than in those with other sickling hemoglobinopathies [38] and is associated with echocardiography-derived tricuspid regurgitant jet velocity [25,54,59,60], increased systemic blood pressure and hypertension [15,38,54,61], and history of stroke [25,48]. These associated comorbidities suggest a shared vasculopathic pathophysiology with albuminuria [25–29]. Albuminuria is also reported to be associated with asymptomatic bacteriuria [52], as well as a history of acute chest syndrome [46,54] and cholelithiasis [48], likely reflecting the role of hemolysis in the pathogenesis of albuminuria. Finally, a recent multicenter cross-sectional study reported an association of proteinuria, assessed by dipstick, with early mortality [62] (Table II).

### Treatment

Improved medical care for individuals with SCD has prolonged their survival, resulting in an increased prevalence of end-organ damage. Albuminuria occurs more commonly with increasing age and may progress to ESRD. Progression to ESRD is often preceded by increasing proteinuria, worsening anemia, and/or the appearance of hypertension [55]. There are no large, controlled studies demonstrating the efficacy of any interventions for albuminuria in SCD. However, treatment of 10 HbSS patients who had proteinuria (0.8–10.8 g/day) with the angiotensin converting enzyme inhibitor, enalapril, for 2 weeks decreased the rate of urinary protein excretion in all patients at the end of the treatment period [7]. This observation was confirmed in a 6-month study in eight HbSS patients with albuminuria [63]. In a double-blind, placebo-controlled study of 22 HbSS patients with microalbuminuria, treatment with captopril resulted in a decrease in microalbuminuria from baseline, while an increase in microalbuminuria was observed in the placebo group [64]. Based on these limited data, angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers have become the "standard of care" for the treatment of albuminuria in SCD (Table III). However, adequately powered controlled studies of these agents are required to evaluate whether they can halt the progression of SCD glomerulopathy and subsequent chronic kidney disease. Hyperkalemia and renal tubular acidosis may occur as manifestations of SCD nephropathy and the use of angiotensin converting enzyme inhibitor therapy may increase the likelihood of hyperkalemia. As such, other effective agents without this side effect are needed in patients with albuminuria. Angiotensin receptor blocking agents are increasingly used instead of angiotensin converting enzyme inhibitors because of their improved tolerability, although there are no published data in SCD to date. Two clinical trials of the angiotensin receptor blocker, losartan, are ongoing (NCT01989078, NCT01479439).

Therapies that improve RBC survival, such as hydroxyurea, or those that improve endothelial function may be beneficial. In a retrospective study, three HbSS children with nephrotic range proteinuria on treatment with enalapril had a near-normal urine protein-creatinine ratio following the addition of hydroxyurea [65]. Further observational studies suggest that hydroxyurea may reduce albuminuria and slow the development of hyperfiltration [50,54,66]. Young age at start of chronic RBC transfusion has also been suggested to provide protection against the development of albuminuria [45], although there are no controlled studies in this setting.

As nonsteroidal anti-inflammatory agents can produce significant declines in the rates of glomerular filtration and renal blood flow in SCD [67,68], and can increase the rate of progression to ESRD, these agents should be used with caution in patients with evidence of glomerulopathy. In addition, effective treatment of hypertension has been reported to delay the progression to ESRD in SCD patients [69], and careful attention to blood pressure control is important in these patients. Despite reports of relative hypertension and its possible...
The prevention of sickle cell glomerulopathy and subsequent chronic kidney disease ultimately depends upon the development of an early cure for SCD. Until gene therapy fulfills its enormous promise, the only currently available curative modality for SCD is bone marrow transplantation (BMT). However, the availability of BMT remains limited. The ability to confidently identify those young patients who are at the highest risk for severe disease will make it possible to select the most appropriate candidates for BMT long before end-organ damage becomes manifest. In addition, early involvement of nephrologists in the treatment of patients with albuminuria may be beneficial.

### Conclusions and Need for Future Studies

SCD is often complicated by a glomerulopathy, which commonly manifests as albuminuria. Although the natural history of albuminuria in SCD remains poorly defined, patients who exhibit albuminuria are more likely to develop ESRD. With the association of ESRD and an increased risk of mortality, early identification and treatment of albuminuria may decrease the risk of death in SCD. Further, due to its association with other SCD-related complications, albuminuria may be a useful biomarker for vasculopathic complications in SCD. The pathophysiology of albuminuria in SCD is likely multifactorial, with contributions from hyperfiltration, glomerular hypertension, ischemia-reperfusion injury, oxidative stress, decreased NO bioavailability, and endothelial dysfunction. Although most patients with albuminuria are treated with angiotensin converting enzyme inhibitors/angiotensin receptor blockers, there are no long-term data on the efficacy of these agents. With the limited data on these agents, combined with their side effect profile, other treatment agents are needed. In view of the improved patient survival following kidney transplantation, more SCD patients with ESRD should be considered for this treatment modality.

Given the high prevalence of albuminuria and its association with multiple SCD-related clinical complications, additional studies are clearly required to answer several clinically important questions in a bid to elucidate its pathophysiology, natural history, and treatment. What are the long-term renal consequences of albuminuria in SCD? Is spot urine quantification of albuminuria reliable in SCD? Can albuminuria serve as a suitable biomarker of renal and other vasculopathic complications in SCD? Will screening for microalbuminuria detect kidney disease earlier? Will treatment of microalbuminuria delay the progression to overt proteinuria and chronic kidney disease in SCD? Does treatment with opioid analgesics worsen albuminuria in SCD? Does treatment of proteinuria with angiotensin converting enzyme inhibitors/angiotensin receptor blockers lead to long-term benefit and attenuation of chronic kidney disease? Do hydroxyurea and other agents that improve RBC survival, increase NO bioavailability and improve endothelial function have a role in the treatment of SCD glomerulopathy? Only through carefully designed clinical and laboratory studies will these questions be answered.

### Author Contributions

KIA, VKD, and DRA wrote the paper.

### Acknowledgment

Support for this work was also provided by an award from the North Carolina State Sickle Cell Program (KIA).
References